DK0734729T3 - Anvendelse af en CGRP-antagonist til behandling af hudrødme af neurogen oprindelse og den opnåede sammensætning - Google Patents

Anvendelse af en CGRP-antagonist til behandling af hudrødme af neurogen oprindelse og den opnåede sammensætning

Info

Publication number
DK0734729T3
DK0734729T3 DK96400457T DK96400457T DK0734729T3 DK 0734729 T3 DK0734729 T3 DK 0734729T3 DK 96400457 T DK96400457 T DK 96400457T DK 96400457 T DK96400457 T DK 96400457T DK 0734729 T3 DK0734729 T3 DK 0734729T3
Authority
DK
Denmark
Prior art keywords
composition obtained
cgrp antagonist
treat skin
skin redness
neurogenic origin
Prior art date
Application number
DK96400457T
Other languages
English (en)
Other versions
DK0734729T4 (da
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0734729(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Publication of DK0734729T3 publication Critical patent/DK0734729T3/da
Application granted granted Critical
Publication of DK0734729T4 publication Critical patent/DK0734729T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
DK96400457T 1995-03-28 1996-03-04 Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning DK0734729T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503628A FR2732221B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue

Publications (2)

Publication Number Publication Date
DK0734729T3 true DK0734729T3 (da) 1999-04-19
DK0734729T4 DK0734729T4 (da) 2004-10-25

Family

ID=9477498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96400457T DK0734729T4 (da) 1995-03-28 1996-03-04 Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning

Country Status (15)

Country Link
US (2) US5932215A (da)
EP (1) EP0734729B2 (da)
JP (1) JPH08268874A (da)
AR (1) AR002974A1 (da)
AT (1) ATE168011T1 (da)
BR (1) BR9601478A (da)
CA (1) CA2172777C (da)
DE (1) DE69600399T3 (da)
DK (1) DK0734729T4 (da)
ES (1) ES2121461T5 (da)
FR (1) FR2732221B1 (da)
HU (1) HUP9600765A3 (da)
MX (1) MX9601150A (da)
PL (1) PL313515A1 (da)
RU (1) RU2152798C1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
WO2002089743A2 (en) * 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
BR0313388A (pt) 2002-08-12 2005-07-05 Birkir Sveinsson Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
AU2005286733B2 (en) * 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ES2664421T3 (es) 2005-11-14 2018-04-19 Teva Pharmaceuticals International Gmbh Anticuerpo antagonista dirigido contra un péptido relacionado con el gen de la calcitonina
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
EP2307001A1 (en) * 2008-06-11 2011-04-13 BioChemics, Inc. Control of blood vessel physiology to treat skin disorders
CA2749941C (en) 2008-09-10 2018-04-24 Biochemics, Inc. Ibuprofen for topical administration
MX349176B (es) 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
US9278233B2 (en) 2008-12-04 2016-03-08 Biochemics, Inc. Methods and compositions for tattoo removal
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
WO2011024113A1 (en) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
US9629856B2 (en) * 2010-03-03 2017-04-25 Anteis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
MX2012010824A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
CN108373502B (zh) 2011-05-20 2022-03-22 H.伦德贝克公司 抗cgrp组合物及其用途
KR102098546B1 (ko) 2011-05-20 2020-04-07 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
DK3119431T3 (da) 2014-03-21 2024-03-18 Teva Pharmaceuticals Int Gmbh Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2017001433A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
EP3515937A1 (en) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating refractory migraine
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
TW263498B (da) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
JP3560977B2 (ja) * 1994-03-21 2004-09-02 トムセン，ジョン ブラウン 皮膚疾患の治療のための及びその皮膚の消毒のためのゲル
EP0704210B1 (fr) * 1994-09-30 2002-12-04 L'oreal Utilisation d'une substance agoniste d'un récepteur associé à un canal chlore dans le traitement des rides
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728265A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
MX9601150A (es) 1997-02-28
HUP9600765A2 (en) 1997-06-30
DE69600399T3 (de) 2005-07-14
RU2152798C1 (ru) 2000-07-20
US6509014B1 (en) 2003-01-21
DE69600399T2 (de) 1998-10-29
DE69600399D1 (de) 1998-08-13
EP0734729A1 (fr) 1996-10-02
JPH08268874A (ja) 1996-10-15
FR2732221B1 (fr) 1997-04-25
CA2172777A1 (fr) 1996-09-29
BR9601478A (pt) 1998-06-02
EP0734729B1 (fr) 1998-07-08
PL313515A1 (en) 1996-09-30
US5932215A (en) 1999-08-03
CA2172777C (fr) 2007-07-24
ES2121461T3 (es) 1998-11-16
FR2732221A1 (fr) 1996-10-04
HUP9600765A3 (en) 1998-04-28
AR002974A1 (es) 1998-05-27
ES2121461T5 (es) 2005-05-01
HU9600765D0 (en) 1996-05-28
ATE168011T1 (de) 1998-07-15
EP0734729B2 (fr) 2004-09-29
DK0734729T4 (da) 2004-10-25

Similar Documents

Publication Publication Date Title
DK0734729T4 (da) Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning
DK0723774T3 (da) Anvendelse af en antagonist for CGRP i en kosmetisk, farmaceutisk eller dermatologisk sammensætning og den opnåede sammensæ
PT1123255E (pt) Coluna de bolhas e sua utilizacao
KR970706257A (ko) 치환된 피리딘의 구충제 및 살진균제로서의 용도(use of substituted pyridines as pest-control agents and fungicides)
NO954239D0 (no) Heterocykliske forbindelser og deres fremstilling og anvendelse
FI932517A0 (fi) Antagonister av angiotensin II
NO983187L (no) Substituerte aza- og diazacykloheptan og -cyklooktan-forbindelse og deres anvendelse
NO20015274L (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
EE200000093A (et) Agrekanaasi ja maatriksmetalloproteinaaside uudsed inhibiitorid artriidi käitlemiseks
NO972477D0 (no) Meso-mono-jod substituerte tetramakrocykliske forbindelser og fremgangsmåter for fremstilling og anvendelse
DK0722722T4 (da) Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse
LV11465A (lv) Heterocikliski amidini panemiens to iegusanai un pielietojums
FR2779638B1 (fr) Composition cosmetique contenant un polysaccharide et un terpolymere acrylique et utilisation de cette composition pour le traitement des matieres keratiniques
DE69801878T2 (de) Verwendung von Oxamatderivaten als Depigmentierungsmittel
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
DK0734730T3 (da) Anvendelse af en CGRP-antagonist til behandling af øjen- eller øjenlågskløe og -dysæstesier
FR2732220B1 (fr) Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
BR9711842A (pt) Derivados de n-(benzotiazol-2-il) piperidina-1-etanamina sua prepara-Æo e sua aplica-Æo em terap-utica
DE29503057U1 (de) Personenschutzvorrichtung für den Sport- oder Freizeitbereich
KR960024734U (ko) 피아노 해머의 타현 방지 장치의 생크 스토퍼
KR920007957U (ko) 비탈면 수로 겸용 보호블럭
DK0917827T3 (da) Fremgangsmåde til fremstilling af flæsk og den særlige anvendelse af det ifølge denne fremgangsmåde fremstillede flæsk
KR950003884U (ko) 세면대 배수전용 마개보턴의 결합구조
KR940022795U (ko) 배수관 연결부의 고정쐐기